Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by approximately 20% at 1 year in patients with overweight or obesity, according to a presentation.Results from a double-blind, dose-ranging phase 2 study of maridebart cafraglutide (MariTide, Amgen) were presented at the World Congress on Insulin Resistance, Diabetes and Cardiovascular
By Staff: Plans are well underway for the ENDO 2025 Poster Hall, one of our annual meeting’s largest and most anticipated events. Our abstract submissions…
No link was found between Competitive Bidding Program implementation and changes in supplemental oxygen use or clinical outcomes in a population of Medicare beneficiaries with…
Among adults in California, those who identified as multiracial had greater lifetime and current asthma prevalences vs. the monoracial populations they shared identities with, according…
Follow these steps to manage your diabetes, avoid complications, and live a long, active life.
A once-daily dose of ivarmacitinib reduced disease activity and improved function among patients with rheumatoid arthritis through 52 weeks, according to phase 3 trial results…
The CDC has awarded Weill Cornell Medicine a 5-year, $2.3 million grant to advance equitable access to care for young patients with breast cancer. The…
Read articles appearing in the print edition of Ocular Surgery News U.S. Edition. Healio is your trusted source for medical news.
Cushing’s syndrome is a condition caused by prolonged exposure to high levels of a stress hormone, cortisol (glucocorticoid hormones). Learn more about Cushing’s syndrome, its…
Weight gain after a breast cancer diagnosis elevated a person’s risk for heart failure, according to results of an observational study in the Republic of…
